戻る
Prelude Therapeutics Inc (PRLD)価格
PRLD 株価推移チャート
PRLD 収入
Prelude Therapeutics Inc
$1.81
-15.81%
$-0.33
終値： Jan 16, 16:00:00 GMT-5
$1.84
1.93%
$0.03
プレマーケット： Jan 20, 05:44:22 GMT-5
主要データ
前終値
$2.15
始値
$2.1
当日レンジ
$1.78 - $2.1
52週レンジ
$0.6101 - $4.22
取引高
1.4M
平均取引高
1.1M
1株当たり利益(TTM)
-0.64
配当利回り
--
時価総額
$115.9M
PRLDとは何ですか？
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.